WO2015183963A3 - Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations - Google Patents
Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations Download PDFInfo
- Publication number
- WO2015183963A3 WO2015183963A3 PCT/US2015/032689 US2015032689W WO2015183963A3 WO 2015183963 A3 WO2015183963 A3 WO 2015183963A3 US 2015032689 W US2015032689 W US 2015032689W WO 2015183963 A3 WO2015183963 A3 WO 2015183963A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phe
- active
- parabenzoquinones
- lys
- arg
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000004057 1,4-benzoquinones Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010048898 phenylalanyl-arginyl-phenylalanyllysinamide Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des procédés et des compositions de traitement et/ou de prévention de maladies ou d'états pathologiques consistant à administrer des parabenzoquinones à activité redox (RPBQ), et/ou des dérivés ou des analogues de ceux-ci d'origine naturelle ou artificielle, ou des sels de ceux-ci pharmaceutiquement acceptables, seuls ou en combinaison avec un ou plusieurs agents actifs (p. ex. un peptide aromatique-cationique). La présente technologie concerne des compositions à base de peptides aromatiques-cationiques liés à des RPBQ, ainsi que des utilisations de ces compositions. Dans certains modes de réalisation, le peptide aromatique-cationique comprend un composé 2',6'-diméthyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2 ou D-Arg-2',6'-Dmt-Lys-Phe-NH2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462003718P | 2014-05-28 | 2014-05-28 | |
US62/003,718 | 2014-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015183963A2 WO2015183963A2 (fr) | 2015-12-03 |
WO2015183963A3 true WO2015183963A3 (fr) | 2016-01-21 |
Family
ID=54700042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/032689 WO2015183963A2 (fr) | 2014-05-28 | 2015-05-27 | Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015183963A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102236829B1 (ko) | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 유사체 및 이의 용도 |
CA2949215C (fr) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | Antagonistes du peptide thioether .alpha.4.beta.7 integrine |
CA2955460A1 (fr) | 2014-07-17 | 2016-01-21 | Protagonist Therapeutics, Inc. | Peptides inhibiteurs par voie orale du recepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin |
BR112017006826A2 (pt) | 2014-10-01 | 2017-12-12 | Protagonist Therapeutics Inc | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017106803A1 (fr) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Dérivés fluoroalkyle, fluoroalcoxy, phénoxy, hétéroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif |
CA3009834A1 (fr) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree |
US20200121618A1 (en) * | 2017-04-14 | 2020-04-23 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
EP4092038A1 (fr) * | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Peptides d'agoniste opioïde et leurs utilisations |
WO2019157268A1 (fr) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Mimétiques d'hepcidine conjugués |
PL3866772T3 (pl) | 2018-10-17 | 2024-04-08 | Ptc Therapeutics, Inc. | 2,3,5-trimetylo-6-nonylocykloheksa-2,5-dieno-1,4-dion do hamowania i leczenia alfa-synukleinopatii, tauopatii i innych zaburzeń |
JP2022540154A (ja) | 2019-07-10 | 2022-09-14 | プロタゴニスト セラピューティクス, インコーポレイテッド | インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
KR20220078644A (ko) | 2019-10-04 | 2022-06-10 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체 |
CN118005737A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
BR112022014011A2 (pt) | 2020-01-15 | 2022-12-20 | Janssen Biotech Inc | Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias |
EP4247403A1 (fr) | 2020-11-20 | 2023-09-27 | JANSSEN Pharmaceutica NV | Compositions d'inhibiteurs peptidiques du récepteur de l'interleukine-23 |
WO2023283466A1 (fr) | 2021-07-08 | 2023-01-12 | Ptc Therapeutics, Inc. | Compositions pharmaceutiques comprenant de la 2,3,5-triméthyl-6-nonylcyclohexa -2,5-diène-1,4-dione |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040029796A1 (en) * | 2000-07-18 | 2004-02-12 | Hazel Szeto | Medicinal uses of mu-opioid receptor agonists |
US20100273892A1 (en) * | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
WO2012170773A1 (fr) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Traitement adjuvant au traitement des maladies mitochondriales avec des quinones et des naphtoquinones |
US20130303436A1 (en) * | 2012-12-06 | 2013-11-14 | Stealth Peptides Internatioanl, Inc. | Peptide therapeutics and methods for using same |
WO2014039862A1 (fr) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Dérivés quinone destinés à être utilisés dans la modulation de l'état d'oxydoréduction chez des individus |
-
2015
- 2015-05-27 WO PCT/US2015/032689 patent/WO2015183963A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040029796A1 (en) * | 2000-07-18 | 2004-02-12 | Hazel Szeto | Medicinal uses of mu-opioid receptor agonists |
US20100273892A1 (en) * | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
WO2012170773A1 (fr) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Traitement adjuvant au traitement des maladies mitochondriales avec des quinones et des naphtoquinones |
WO2014039862A1 (fr) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Dérivés quinone destinés à être utilisés dans la modulation de l'état d'oxydoréduction chez des individus |
US20130303436A1 (en) * | 2012-12-06 | 2013-11-14 | Stealth Peptides Internatioanl, Inc. | Peptide therapeutics and methods for using same |
Non-Patent Citations (1)
Title |
---|
SHRADER, WD ET AL.: "Alpha-Tocotrienol Quinone Modulates Oxidative Stress Response And The Biochemistry Of Aging.", BIOORG MED CHEM LETT., vol. 21, no. 12, 15 June 2011 (2011-06-15), pages 3693 - 3698, XP002663593, DOI: doi:10.1016/J.BMCL.2011.04.085 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015183963A2 (fr) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015183963A3 (fr) | Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations | |
WO2016004093A3 (fr) | Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci | |
WO2015183995A3 (fr) | Compositions thérapeutiques comprenant de la frataxine, de la lactoferrine et des enzymes mitochondriales génératrices d'énergie et leurs utilisations | |
WO2014165607A3 (fr) | Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation | |
WO2014205317A3 (fr) | Peptides cycliques utilisés en tant qu'agents de ciblage de protéines | |
WO2017044894A3 (fr) | Peptides localisant le cartilage | |
PH12015502002A1 (en) | Tripeptide epoxy ketone protease inhibitors | |
MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
WO2015070224A3 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
MX2017015105A (es) | Compuestos del peptido yy (pyy) selectivos y sus usos. | |
MX2019012884A (es) | Terapia de combinacion. | |
WO2017100700A3 (fr) | Peptides pour thérapie rénale | |
CA3010568A1 (fr) | Supports nanofibreux oromumuqueux pour traitement therapeutique | |
NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
JO3326B1 (ar) | مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد | |
UA111599C2 (uk) | Композиція каспофунгіну | |
WO2012053013A3 (fr) | Compositions pharmaceutiques d'agents anti-acné | |
EP4342461A3 (fr) | Compositions pharmaceutiques et utilisations contre des troubles du stockage lysosomal | |
MX2022013450A (es) | Formulaciones farmaceuticas. | |
NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
WO2016015798A9 (fr) | Composition de film orodispersible, comprenant de l'énalapril pour le traitement de l'hypertension dans une population pédiatrique | |
WO2015183985A3 (fr) | Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations | |
MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15798679 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/03/2017) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15798679 Country of ref document: EP Kind code of ref document: A2 |